Combination Strategy Overcomes Drug Resistance in Preclinical Breast Cancer Models
Researchers at UT MD Anderson used a computational platform to uncover a dual-drug approach that suppressed tumor growth in treatment-resistant breast cancer models.
🧠AI AnalysisPhoto: Medical Xpress
Key points
- UT MD Anderson researchers used a computational algorithm called TargetScore to identify cellular backup routes that drive drug resistance.
- Simultaneously inhibiting the PARP and SHP2 pathways slowed tumor growth and extended survival in preclinical breast cancer models.
- Clinical trials will be needed to confirm whether this combination therapy is safe and effective in human patients.
Researchers at The University of Texas MD Anderson Cancer Center have identified a dual-drug strategy that successfully bypassed treatment resistance in laboratory models of advanced breast cancer. The findings, published in the journal Cancer Research, relied on a novel computational algorithm called TargetScore to track how cancer cells adapt when exposed to therapeutic stress.
Investigators led by Anil Korkut, Ph.D., used TargetScore to analyze cellular responses after targeting MCL1, a protein that allows cancer cells to avoid programmed cell death. The algorithm revealed that under stress, breast cancer cells activated secondary survival routes governed by the PARP and SHP2 proteins, which control DNA repair and cellular growth. When researchers simultaneously inhibited both PARP and SHP2, the combination therapy significantly slowed tumor growth and prolonged survival in preclinical models compared to single-drug approaches. The effect was notably pronounced in cells with DNA repair defects that had already developed resistance to therapy.
What to know: These findings are based strictly on preclinical cell and animal models. While the computational approach highlights a potential strategy to counter drug resistance, clinical trials are necessary to confirm whether dual PARP and SHP2 inhibition is safe and effective for human patients. Individuals currently receiving treatment for breast cancer should discuss therapeutic options directly with their healthcare team.
Source Medical Xpress — medicalxpress.com/news/2026-11-combination-therapy-treatment-resistance… ↗
Read next
🏃FitnessUnderstanding and Addressing Love Handles Through Lifestyle Changes
Experts clarify that spot reduction of fat is not physiologically possible, recommending a combination of calorie management and high-intensity interval training instead.
🏃FitnessCiele Releases New Woolmark-Certified Merino Winter Running Apparel
Montreal-based brand Ciele has launched its second collection of merino wool running gear, featuring performance-focused fabrics designed for cold-weather training.
🏥Public HealthPreventive Services Task Force Resumes Meetings Under New Leadership
The U.S. Preventive Services Task Force is set to reconvene this week for the first time in over a year following a significant membership overhaul by Health Secretary Ro…
❤️Conditions & CareBlood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma
Researchers have identified a specific RNA signature in blood plasma that may help predict how well lymphoma patients respond to CAR T-cell therapy.
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
❤️Conditions & CareMigraine and Smoking Linked to Increased Early Stroke Risk in Women
A large-scale study suggests that people who have given birth and experience migraines while also smoking face a significantly higher risk of stroke before age 60.